The Drive to Discover. The Experience to Deliver.
Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8,000 employees in 50 countries. Mr. Hoppenot joined Novartis in 2003 and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a Diploma from ESSEC International Business School.
Jim Daly joined Incyte as Executive Vice President and Chief Commercial Officer in October 2012. Prior to joining Incyte, he held multiple leadership positions at Amgen, Inc. In his last role, Mr. Daly was Senior Vice President, responsible for North America Commercial Operations as well as Global Marketing and Commercial Development. From 2001 to 2005, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. Previously, Mr. Daly spent 17 years with Glaxo Wellcome/GlaxoSmithKline in the United States and abroad. Mr. Daly earned his undergraduate degree in Pharmacy and his Master’s degree in Business Administration from the State University of New York in Buffalo.
Barry P. Flannelly, Pharm.D., MBA, joined Incyte as Executive Vice President, Business Development and Strategic Planning, in August 2014. Dr. Flannelly has more than 17 years of experience in business development, commercial, medical affairs and strategic planning. Prior to joining Incyte, he served as Chief Executive Officer of OSS Healthcare Inc., a biotech start-up. He also held key positions at companies such as Nektar Therapeutics, Onyx Pharmaceuticals, Abraxis Oncology, and Novartis. Dr. Flannelly earned his doctorate in pharmacy from the University of Maryland, School of Pharmacy, his master’s degree in business administration from the University of Baltimore, and his B.S. degree in Pharmacy from Massachusetts College of Pharmacy.
David C. Hastings joined Incyte as Executive Vice President and Chief Financial Officer in October 2003. Before joining Incyte, Mr. Hastings was Chief Financial Officer and Treasurer at ArQule, Inc. Prior to joining ArQule, he was with Genzyme, as Vice President, Corporate Controller, and prior to Genzyme he spent three years as Director of Finance at Sepracor, Inc. From 1985 to 1994, Mr. Hastings was with PriceWaterhouseCoopers. Mr. Hastings is a Certified Public Accountant and received his B.A. in economics from the University of Vermont.
Reid M. Huber joined Incyte in January 2002 as Associate Director, Applied Technology. For the past 10 years, Dr. Huber has held roles of increasing responsibility in both drug discovery and clinical development at Incyte, most recently as Executive Director, Clinical Development. Prior to joining Incyte, Dr. Huber held scientific research positions with DuPont Pharmaceuticals Company from 1998 to 2002. Dr. Huber held intramural pre-doctoral and post-doctoral fellowships at the National Institutes of Health from 1997-1998. Dr. Huber received his B.S. in biochemistry/molecular genetics from Murray State University and his Ph.D. in molecular genetics from Washington University.
Richard S. Levy joined Incyte as Senior Vice President, Drug Development in August 2003. Dr. Levy has over 20 years of experience in the pharmaceutical and biotechnology sectors through his prior positions at Celgene, DuPont Pharmaceuticals and Novartis. Dr. Levy has extensive clinical research, regulatory and product development skills and has worked in multiple therapeutic areas including HIV, cancer and inflammation. Prior to joining Incyte, Dr. Levy served as Vice President, Biologic Therapies at Celgene where he was responsible for clinical development and regulatory affairs for the Cellular Therapeutics Division. Prior to Celgene, from 1997 to 2002, he was with DuPont Pharmaceuticals first as Vice President of Regulatory Affairs and Pharmacovigilence and then as Vice President, Medical and Commercial Strategy. In these positions, he played an important role in the development, registration, approval and commercialization of Sustiva, a leading anti-HIV drug. He was at Novartis from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. Dr. Levy received his M.D. from the University of Pennsylvania School of Medicine.
Victor Sandor joined Incyte as Vice President Global Oncology Drug Development in February 2010, and after taking on additional responsibilities, he became Senior Vice President, Drug Development in May 2014. Dr. Sandor has experience across the drug development life cycle in oncology, having worked on the development of products at early stages of development as well as with late-stage and marketed products. Before joining Incyte, Dr. Sandor was Vice President of Clinical Oncology at Biogen Idec, and prior to that he led the U.S.-based emerging product effort in oncology at AstraZeneca. Dr. Sandor is a board-certified medical oncologist with experience in both academic and private oncology practice. He completed his medical oncology training at the National Cancer Institute in Bethesda, MD, and earned his medical degree (MD,CM) from McGill University in Montreal.
Eric H. Siegel joined Incyte as our Chief Compliance Officer in October 2010 and became Executive Vice President and General Counsel in August 2011. Prior to joining Incyte, from April 2009 to October 2011, he was Chief Compliance Officer at EMD Serono, a privately held biotechnology company. From 2007 to 2009 he served as General Counsel for Solstice Neurosciences, also a privately held biotechnology company. He was Vice President, Deputy General Counsel and Chief Compliance Officer at Cephalon from 2004 to 2007. Mr. Siegel holds a B.A. from Franklin and Marshall College, his M.B.A. from Temple University and his J.D. from the University of Pennsylvania.
Paula J. Swain joined Incyte in January 2002 and serves as Executive Vice President of Human Resources. Prior to joining the company, Ms. Swain spent nearly 10 years with DuPont Pharmaceuticals Company (acquired by Bristol-Myers Squibb Company in 2001) where she served as Vice President and Senior Vice President of Human Resources. She has also held human resource planning and employee relations positions with Chase Manhattan Bank, Marine Midland Bank and Delaware Trust Company. Ms. Swain received her B.A. in psychology from Rockhurst College and graduated from the strategic human resources planning program at Harvard Business School.
Wenqing Yao joined Incyte in February 2002 as Director, Chemistry. Dr. Yao has over 20 years of experience in medicinal chemistry. For the past nine years, Dr. Yao has held roles of increasing responsibility at Incyte, most recently as Vice President, Chemistry. Prior to joining Incyte, Dr. Yao held scientific research positions with DuPont Pharmaceuticals and Bristol-Myers Squibb Company from 1996 to 2002. Dr. Yao received his B.S. in chemistry from Xuzhou Normal University, his M.S. in organic chemistry from NanKai University and his Ph.D. in organic/medicinal chemistry from the University of Pennsylvania.
- About Incyte
- Jakafi® (ruxolitinib)
- Disease Education